Enterprise Value
329.7M
Cash
202.9M
Avg Qtr Burn
-17.97M
Short % of Float
10.73%
Insider Ownership
7.53%
Institutional Own.
79.15%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belzupacap Sarotalocan (Bel-sar) Details Primary Choroidal Melanoma | Phase 3 Data readout | |
Belzupacap Sarotalocan (Bel-sar) (Suprachoroidal (SC) Administration) Details Choroidal Metastasis | Phase 2 Data readout | |
Belzupacap Sarotalocan (Bel-sar) Details Non-muscle invasive bladder cancer, Muscle-invasive bladder cancer | Phase 1 Data readout |